

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **December 9, 2010**

AETHLON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction
of incorporation)

000-21846
(Commission
File Number)

13-3632859
(I.R.S. Employer
Identification No.)

8910 University Center Lane, Suite 660
San Diego, California
(Address of principal executive offices)

92122
(Zip Code)

Registrant's telephone number, including area code: **(858) 459-7800**

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ~~Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))~~
-

Item 7.01 Regulation FD Disclosure

The Registrant reported today that on December 9, 2010 at 11:30 a.m. PST it made a presentation at the 2010 LD Micro Conference in Los Angeles, California. A copy of the investor presentation materials are being furnished as an exhibit to this report and are incorporated by reference into this Item 7.01. The Registrant posted the investor presentation materials to its website today, December 10, 2010.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibit is being furnished pursuant to Item 7.01 above.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Investor Presentation Materials

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC.
(Registrant)

Date: December 10, 2010

By: /s/ James B. Frakes
James B. Frakes
Chief Financial Officer

EXHIBIT INDEX

Exhibit No.

Description

99.1

Investor Presentation Materials

JIM JOYCE
CHAIRMAN, CEO

LD MICRO CONFERENCE

December 9, 2010





MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING WHETHER AND WHEN OUR PRODUCTS ARE SUCCESSFULLY DEVELOPED AND INTRODUCED, MARKET ACCEPTANCE OF OUR HEMOPURIFIER® AND OTHER PRODUCT OFFERINGS, REGULATORY DELAYS, MANUFACTURING DELAYS, AND OTHER RISKS DETAILED IN OUR SEC FILINGS ACCESSIBLE AT WWW.SEC.GOV.

Forward looking statements



Available Conference Documents

“A Platform Technology to Address
Bioterrorism”

- ▣ 11/18/10

Shareholder Letter

- ▣ 12/1/10

California Equity Research Initiation

- ▣ 12/8/10

WE CREATE REVOLUTIONARY
DEVICES
THAT ADDRESS INFECTIOUS
DISEASE
& CANCER




THE HEMOPURIFIER®

THE FIRST MEDICAL DEVICE TO SELECTIVELY
FILTER VIRUSES AND IMMUNOSUPPRESSIVE
PARTICLES FROM CIRCULATION

Leveraging Established Infrastructure



Selectively Targets the Removal of:



MEDICAL DEVICE VS.
BIOLOGIC REGULATORY
PATHWAY

70 TREATMENT EXPERIENCES IN
HUMANS

SUBSTANTIAL VIRAL LOAD
REDUCTION IN HIV AND HCV
INFECTED INDIVIDUALS

LEADING BROAD-
SPECTRUM
COUNTERMEASURE
AGAINST BIOTERROR &
PANDEMIC THREATS

NEAR-TERM
COMMERCIALIZATION
PATHWAY OVERSEAS

IDE ON FILE WITH THE FDA

GMP MANUFACTURING
ESTABLISHED THROUGH
PARTNERSHIP WITH
NEXTPHARMA TECHNOLOGIES

LOI SIGNED WITH MEMBRANA
FOR LARGE-SCALE
PRODUCTION

HEMOPURIFIER® PROVIDES A
PIPELINE INTO THREE \$ MULTI-
BILLION MARKETS



HCV

- 180m infected
- \$4.4bn in 2009
- \$9.1bn in 2015

HIV

- 33m infected
- \$12bn in 2009
- \$13.7bn in 2016

CANCER

- 12m new cases/yr
 - 7m deaths/yr
 - \$50bn in 2008
 - \$110bn in 2013
-

OUR WILDCARD MARKET
OPPORTUNITY



Bioterror & Pandemic Threats


The Most Advanced Broad-Spectrum
Countermeasure

Virus	Collaborators	Human Variety
Ebola	CDC / USAMRIID	YES
Dengue	NIV / WHO	YES
Lassa	SFBR	YES
West Nile	Battelle	YES
H5N1 Avian	Battelle	YES
Spanish Flu of 1918-R	Battelle	YES
2009 H1N1 Swine	Battelle	YES
Monkey pox	Battelle	NO

“The Hemopurifier® is the only strategy to address the breadth of pathogens that could be weaponized as agents of bioterror”

Ken Alibek

OUR PRIMARY MARKET
FOCUS IS.....




Hepatitis-C Virus (HCV)

TO ACCELERATE EARLY VIRAL LOAD
REDUCTION OF HCV STANDARD OF CARE
(SOC) DRUG THERAPY

IN THE ABSENCE OF DRUG
THERAPY

5 Day HCV Treatment Studies




ONE WEEK STUDY - THREE HEMOPURIFIER®

OUR STRATEGY IS TO
COMBINE OUR
HEMOPURIFIER® WITH HCV-
SOC TO ACCELERATE EARLY
VIRAL DEPLETION

VIRAL FILTRATION HAS BEEN
PROVEN TO IMPROVE HCV
CURE RATES!

Validation for Viral Filtration Therapy

SVR rates of HCV patients who previously failed or relapsed interferon/ribavirin (SOC)




An Enduring Adjunct Opportunity

- Hemopurifier® + Current SOC
 - Hemopurifier® + Future Iterations of SOC
 - ▣ 65 drugs in competition
-

The Hemopurifier® + HCV SOC Study

- Enrollment has been initiated at the Medicity
 - Up to 30 Patients
 - Up to 6 treatments in first 3 days of SOC
 - Clinical endpoints include:
 - ▣ Immediate Virologic Response (IVR)
 - ▣ Rapid Virologic Response (RVR)
 - ▣ Early Virologic Response (EVR)
 - Positive outcomes trigger commercialization
-



Human Immunodeficiency Virus (HIV)


OUR HEMOPURIFIER® IS THE ONLY
TREATMENT STRATEGY TO ADDRESS DRUG
RESISTANT AIDS PATIENTS

DO HIV INFECTED
INDIVIDUALS HAVE TO DIE
WHEN THEY NO LONGER
RESPOND TO THEIR MEDS?


IN THE ABSENCE OF DRUG
THERAPY

HIV/AIDS Patient Data

92% reduction of viral load



Improved CD4+ T-cell %



30 DAY STUDY - THREE HEMOPURIFIER® TREATMENTS PER WEEK


IF YOU HAVE CANCER.....

EXOSOMES ARE SECRETED BY
ALL TUMORS, LYMPHOMAS, &
LEUKEMIAS

Exosomes are Immunosuppressive

- Induce Apoptosis
 - Disrupt T-Cell Signaling
 - Inhibit Cytokine Production
 - Angiogenesis
 - Metastasis
-

Tumor-Secreted Exosomes





OUR HEMOPURIFIER® IS THE
SOLE THERAPEUTIC STRATEGY
TO ADDRESS
IMMUNSUPPRESSIVE EXOSOMES

GOAL IS TO MAXIMIZE THE
ABILITY OF THE IMMUNE
SYSTEM AND/OR OTHER
THERAPIES TO COMBAT
CANCER?

A Complementary Therapeutic

- Targets Benefit w/o
 - Stacking additional drug toxicity
 - Adding drug interaction risk
-





U.S. Clinical Programs

Recent Additions
to the AEMD
Team

September 3rd

FABIANI & COMPANY
ENGAGED
TO REESTABLISH
BIODEFENSE & PANDEMIC
THREAT PROGRAMS

October 26th

MIRIAM PROVOST NAMED
U.S. REGULATORY
ADVISOR

Miriam Provost

- 13 Years at FDA-ODE
 - Deputy Director
 - Division Director
 - Branch Chief
-

October 28th

ROD KENLEY NAMED
PRESIDENT

Rod Kenley

- BAXTER
 - ▣ Conceived the HomeChoice Peritoneal Dialyzer
 - International Marketing Manager
 - Director of Worldwide Product Planning
 - Director of Advanced Product Development
 - AKSYS LTD
 - ▣ Founder
 - ▣ Commercialized the PHD System, the first daily home hemodialysis machine
 - DEKA RESEARCH
-

The HomeChoice® Device



CREATE A PORTABLE
HEMOPURIFIER® TO DELIVER
IN-HOME BENEFIT

Selected 2011 Milestone Targets

- HCV TREATMENT DATA
 - HCV Commercialization
 - Approval to Initiate U.S. Studies
 - Clinical Partners Established in EU
 - Multiple Bioterror Contract/Grant Submissions
 - Cancer
 - Data from multiple studies
 - Disclosure of collaborative partnerships
 - Advance Mobile/In Home Hemopurifier®
-

CREATING REVOLUTIONARY
DEVICES
THAT ADDRESS INFECTIOUS
DISEASE
& CANCER

JIM JOYCE CHAIRMAN, CEO

8910 UNIVERSITY CENTER LANE
SAN DIEGO, CA. 92122

JJ@AETHLONMEDICAL.COM
858.459.7800 X301

ASSISTANT: CHARLENE OWEN
COWEN@AETHLONMEDICAL.COM
858.459.7800 X305



